For example, at least 1 site of a metastatic disease characterized by significantly greater uptake than normal liver on baseline 68Ga-PSMA-11 PET/CT was established as enrollment criterion for 177Lu-PSMA-617 RLT in the single-arm, single-center, phase 2 trial aimed to assess treatment safety, efficacy, and impact on quality of life in mCRPC patients [86]. The gene discussed is FOLH1; the disease is metastatic neoplasm.